Literature DB >> 30190813

Management of 'pan-negative' melanoma: current and emerging strategies.

Douglas B Johnson1,1, Chengwei Peng2,2, Igor Puzanov1,1.   

Abstract

Entities:  

Year:  2014        PMID: 30190813      PMCID: PMC6094662          DOI: 10.2217/mmt.14.21

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN: 2045-0885


× No keyword cloud information.
  19 in total

1.  A landscape of driver mutations in melanoma.

Authors:  Eran Hodis; Ian R Watson; Gregory V Kryukov; Stefan T Arold; Marcin Imielinski; Jean-Philippe Theurillat; Elizabeth Nickerson; Daniel Auclair; Liren Li; Chelsea Place; Daniel Dicara; Alex H Ramos; Michael S Lawrence; Kristian Cibulskis; Andrey Sivachenko; Douglas Voet; Gordon Saksena; Nicolas Stransky; Robert C Onofrio; Wendy Winckler; Kristin Ardlie; Nikhil Wagle; Jennifer Wargo; Kelly Chong; Donald L Morton; Katherine Stemke-Hale; Guo Chen; Michael Noble; Matthew Meyerson; John E Ladbury; Michael A Davies; Jeffrey E Gershenwald; Stephan N Wagner; Dave S B Hoon; Dirk Schadendorf; Eric S Lander; Stacey B Gabriel; Gad Getz; Levi A Garraway; Lynda Chin
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

4.  KIT as a therapeutic target in metastatic melanoma.

Authors:  Richard D Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272

5.  Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.

Authors:  Richard W Joseph; Ryan J Sullivan; Robyn Harrell; Katherine Stemke-Hale; David Panka; George Manoukian; Andrew Percy; Roland L Bassett; Chaan S Ng; Laszlo Radvanyi; Patrick Hwu; Michael B Atkins; Michael A Davies
Journal:  J Immunother       Date:  2012-01       Impact factor: 4.456

6.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Authors:  Paolo A Ascierto; Dirk Schadendorf; Carola Berking; Sanjiv S Agarwala; Carla Ml van Herpen; Paola Queirolo; Christian U Blank; Axel Hauschild; J Thaddeus Beck; Annie St-Pierre; Faiz Niazi; Simon Wandel; Malte Peters; Angela Zubel; Reinhard Dummer
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

Review 7.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Authors:  M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

8.  Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.

Authors:  John Fruehauf; Jose Lutzky; David McDermott; Charles K Brown; Jean-Baptiste Meric; Brad Rosbrook; David R Shalinsky; Katherine F Liau; Andreas G Niethammer; Sinil Kim; Olivier Rixe
Journal:  Clin Cancer Res       Date:  2011-10-05       Impact factor: 12.531

9.  Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.

Authors:  Lawrence N Kwong; James C Costello; Huiyun Liu; Shan Jiang; Timothy L Helms; Aliete E Langsdorf; David Jakubosky; Giannicola Genovese; Florian L Muller; Joseph H Jeong; Ryan P Bender; Gerald C Chu; Keith T Flaherty; Jennifer A Wargo; James J Collins; Lynda Chin
Journal:  Nat Med       Date:  2012-09-16       Impact factor: 53.440

10.  BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

Authors:  Kimberly Brown Dahlman; Junfeng Xia; Katherine Hutchinson; Charles Ng; Donald Hucks; Peilin Jia; Mohammad Atefi; Zengliu Su; Suzanne Branch; Pamela L Lyle; Donna J Hicks; Viviana Bozon; John A Glaspy; Neal Rosen; David B Solit; James L Netterville; Cindy L Vnencak-Jones; Jeffrey A Sosman; Antoni Ribas; Zhongming Zhao; William Pao
Journal:  Cancer Discov       Date:  2012-07-13       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.